Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 6:17:249.
doi: 10.1186/s12891-016-1117-5.

A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout

Jane C Richardson  1 , Jennifer Liddle  2 , Christian D Mallen  2 , Edward Roddy  2 , Samantha Hider  2 , Suman Prinjha  3 , Sue Ziebland  3
Affiliations

A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout

Jane C Richardson et al. BMC Musculoskelet Disord. .

Abstract

Background: Although international guidelines encourage urate lowering therapy (ULT) for people who have more than two attacks of gout, only 30 % of patients are prescribed it and only 40 % of those adhere to the treatment. The aim was to explore reasons for this through an exploration of patient experience and understanding of ULT treatment for gout.

Methods: A qualitative study was conducted throughout the United Kingdom. Narrative and semi-structured video-recorded interviews and thematic analysis were used.

Results: Participants talked about their views and experiences of treatment, and the factors that affected their use of ULT. The analysis revealed five main themes: 1) knowledge and understanding of gout and its treatment; 2) resistance to taking medication; 3) uncertainty about when to start ULT; 4) experiences of using ULT; and 5) desire for information and monitoring.

Conclusion: Patients' understanding and experiences of gout and ULT are complex and it is important for clinicians to be aware of these when working with patients. It is also important for clinicians to know that patients' perceptions and behaviour are not fixed, but can change over time, with changes to their condition, with dialogue and increased understanding. Patients want this interaction with their clinicians, through "a joint effort over a period of time".

Keywords: Gout; Patient perceptions; Primary care; Qualitative; Urate lowering therapy (ULT).

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Factors affecting patients’ use of urate-lowering therapy (ULT) for long-term treatment of gout
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2014;0:1–7. - PMC - PubMed
    1. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3(8):443–9. doi: 10.1038/ncprheum0556. - DOI - PubMed
    1. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, EULAR Standing Committee for International Clinical Studies Including Therapeutics EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis. 2006;65:1301–11. doi: 10.1136/ard.2006.055251. - DOI - PMC - PubMed
    1. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatol (Oxford) 2007;46:1372–4. doi: 10.1093/rheumatology/kem056a. - DOI - PubMed
    1. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Mae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447–61. doi: 10.1002/acr.21773. - DOI - PMC - PubMed

Publication types

MeSH terms